Preclinical evidence is provided for the possibility that MDS patients with SF3B1 mutations may benefit from Chk1 inhibition, thereby exploiting the R-loop-related vulnerability induced by these mutations (37). Here, SF3B1 is linked to myelodysplastic syndrome.